15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Akari Therapeutics PLC, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $1.00 to $30.00 (about 30.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $19.33 sits 143% above the current $7.97. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.46 next quarter toward $-1.17 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Akari Therapeutics PLC.
As of Aug, 3 of 3 firms rate AKTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AKTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.46
Range $-0.92 – $0.00 · 2 analysts
Next period, 2 analysts expect Akari Therapeutics PLC to earn $-0.46 a share (range $-0.92 – $0.00), versus $0.00 a year earlier. Full-year consensus is $-5.33, growing to $-1.17 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Akari Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AKTX.
#1
Sean Lee
HC Wainwright & Co. · Rank #222
Buy
$27.00+238.8% to target
Overall win rate
44%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #417
Buy
$30.00+276.4% to target
Overall win rate
33%
+ Follow
#3
Aydin Huseynov
Ladenburg Thalmann · Rank #422
Buy
$1.00-87.5% to target
Overall win rate
34%
+ Follow
#4
James Molloy
Alliance Global Partners · Rank #445
Buy
$280.00+3413.2% to target
Overall win rate
25%
+ Follow
AKTX stock forecast FAQ
What is AKTX's average 12-month price target?+
The 3 analysts with a live target average $19.33 for Akari Therapeutics PLC over the next 12 months, ranging from a $30.00 high to a $1.00 low.
Is AKTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AKTX?+
The Street-high target is $30.00 (Maxim Group), and the Street-low is $1.00 (Ladenburg Thalmann). The average of all 3 active targets is $19.33.
How many Wall Street analysts cover AKTX?+
3 analysts have an active rating on Akari Therapeutics PLC, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering AKTX?+
Among analysts who currently cover AKTX, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #222). Their current call is Buy with a $27.00 target.
What is Akari Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.46 per share (range $-0.92 – $0.00) across 2 analysts. Full-year EPS is projected at $-5.33, rising to $-1.17 the following year.
How much revenue is Akari Therapeutics PLC expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AKTX lately?+
As of Aug, 3 of 3 firms rate AKTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AKTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
